Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Moss, Nelson S., Singh, Jolene M., Reiner, Anne S., Drago, Joshua Z., Modi, Shanu, Seidman, Andrew D., Chandarlapaty, Sarat, Ross, Dara S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590773/
https://www.ncbi.nlm.nih.gov/pubmed/37867174
http://dx.doi.org/10.1038/s41523-023-00592-5
_version_ 1785124065150763008
author Moss, Nelson S.
Singh, Jolene M.
Reiner, Anne S.
Drago, Joshua Z.
Modi, Shanu
Seidman, Andrew D.
Chandarlapaty, Sarat
Ross, Dara S.
author_facet Moss, Nelson S.
Singh, Jolene M.
Reiner, Anne S.
Drago, Joshua Z.
Modi, Shanu
Seidman, Andrew D.
Chandarlapaty, Sarat
Ross, Dara S.
author_sort Moss, Nelson S.
collection PubMed
description The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced breast cancer with brain metastases may underestimate CNS response potential in the absence of brain metastasis sampling. In this cohort study including 136 patients with 401 samples scored according to ASCO/CAP guidelines, 15/28 patients (54%) with HER2-null primary breast cancer have detectable HER2 expression in subsequently resected brain metastases, a significant discordant population.
format Online
Article
Text
id pubmed-10590773
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105907732023-10-24 Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis Moss, Nelson S. Singh, Jolene M. Reiner, Anne S. Drago, Joshua Z. Modi, Shanu Seidman, Andrew D. Chandarlapaty, Sarat Ross, Dara S. NPJ Breast Cancer Brief Communication The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced breast cancer with brain metastases may underestimate CNS response potential in the absence of brain metastasis sampling. In this cohort study including 136 patients with 401 samples scored according to ASCO/CAP guidelines, 15/28 patients (54%) with HER2-null primary breast cancer have detectable HER2 expression in subsequently resected brain metastases, a significant discordant population. Nature Publishing Group UK 2023-10-23 /pmc/articles/PMC10590773/ /pubmed/37867174 http://dx.doi.org/10.1038/s41523-023-00592-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Moss, Nelson S.
Singh, Jolene M.
Reiner, Anne S.
Drago, Joshua Z.
Modi, Shanu
Seidman, Andrew D.
Chandarlapaty, Sarat
Ross, Dara S.
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
title Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
title_full Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
title_fullStr Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
title_full_unstemmed Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
title_short Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
title_sort incidence of her2-expressing brain metastases in patients with her2-null breast cancer: a matched case analysis
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590773/
https://www.ncbi.nlm.nih.gov/pubmed/37867174
http://dx.doi.org/10.1038/s41523-023-00592-5
work_keys_str_mv AT mossnelsons incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT singhjolenem incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT reinerannes incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT dragojoshuaz incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT modishanu incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT seidmanandrewd incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT chandarlapatysarat incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis
AT rossdaras incidenceofher2expressingbrainmetastasesinpatientswithher2nullbreastcanceramatchedcaseanalysis

Ejemplares similares